We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Join our healthcare community
Explore a comprehensive guide to Fintepla dosage for Dravet and Lennox-Gastaut Syndromes. Learn about administration, titration, side effects, and vital safety considerations for this epilepsy medication.
Fintepla (fenfluramine) is a prescription medication used to treat seizures associated with Dravet Syndrome and Lennox-Gastaut Syndrome (LGS) in patients aged 2 years and older. These are rare and severe forms of epilepsy that often begin in childhood and are challenging to manage. Understanding the correct dosage, administration, and potential side effects of Fintepla is crucial for effective treatment and patient safety. This comprehensive guide will walk you through everything you need to know about Fintepla dosage, from initial titration to special considerations.
Fintepla, with the active ingredient fenfluramine, is an oral solution that works on the central nervous system. While its exact mechanism of action in treating epilepsy is not fully understood, it is believed to modulate serotonergic transmission, which plays a role in seizure control. It is important to note that Fintepla is part of a Risk Evaluation and Mitigation Strategy (REMS) program due to its potential for serious side effects, particularly valvular heart disease and pulmonary arterial hypertension, which necessitate regular monitoring.
Before initiating Fintepla treatment, your doctor will conduct a thorough evaluation to ensure it's the right choice for you or your child. Key considerations include:
Fintepla is typically started at a low dose and gradually increased (titrated) over several weeks. This titration process allows the body to adjust to the medication and helps minimize side effects. The goal is to find the lowest effective dose that controls seizures while minimizing adverse reactions. It is crucial to follow your doctor's specific dosing instructions precisely and never adjust the dose on your own.
For patients with Dravet Syndrome, Fintepla is administered as an oral solution. The dosage is based on body weight and is carefully titrated.
The recommended starting dose for Fintepla in Dravet Syndrome is 0.1 mg/kg twice daily (0.2 mg/kg/day). The maximum initial dose should not exceed 13 mg per day.
The dose can be increased weekly in increments of 0.1 mg/kg twice daily (0.2 mg/kg/day), up to a maximum of 0.35 mg/kg twice daily (0.7 mg/kg/day), or 26 mg/day, whichever is less. However, if the patient is also taking stiripentol, the maximum daily dose of Fintepla should not exceed 0.2 mg/kg twice daily (0.4 mg/kg/day), or 17 mg/day, whichever is less. Your doctor will carefully monitor your response and tolerance during this period.
The maximum recommended daily dose of Fintepla for Dravet Syndrome is 0.7 mg/kg/day or 26 mg/day, whichever is less. If stiripentol is co-administered, the maximum daily dose is 0.4 mg/kg/day or 17 mg/day, whichever is less.
Similar to Dravet Syndrome, Fintepla dosage for LGS is carefully titrated based on body weight.
The recommended starting dose for Fintepla in LGS is 0.1 mg/kg twice daily (0.2 mg/kg/day). The maximum initial dose should not exceed 13 mg per day.
The dose can be increased weekly in increments of 0.1 mg/kg twice daily (0.2 mg/kg/day), up to a maximum of 0.35 mg/kg twice daily (0.7 mg/kg/day), or 26 mg/day, whichever is less. Your doctor will adjust the dose based on your individual response and tolerability.
The maximum recommended daily dose of Fintepla for LGS is 0.7 mg/kg/day or 26 mg/day, whichever is less.
Several factors can influence the appropriate Fintepla dosage, necessitating adjustments by your healthcare provider.
Your doctor will perform liver function tests to determine the severity of any impairment and adjust the dose accordingly.
For patients with moderate or severe renal impairment, the starting dose and maximum daily dose may need to be reduced. Your doctor will assess kidney function and make appropriate adjustments to prevent drug accumulation and potential toxicity.
Certain medications can affect the metabolism of Fintepla, leading to increased or decreased levels of the drug in the body. For instance:
Always inform your doctor about all prescription and over-the-counter medications, as well as herbal supplements, you are taking.
Fintepla is an oral solution that should be measured and administered carefully.
If you miss a dose of Fintepla, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one, as this can increase the risk of side effects.
An overdose of Fintepla can be serious and may lead to symptoms such as agitation, confusion, hallucinations, increased heart rate, high blood pressure, dilated pupils, muscle stiffness, and severe drowsiness. If you suspect an overdose, seek immediate medical attention or call emergency services.
Like all medications, Fintepla can cause side effects. Many are mild and temporary, but some can be serious. Common side effects include:
Fintepla carries several important warnings due to the potential for serious adverse effects:
The cost of Fintepla can be substantial, as it is a specialized medication for rare conditions. Prices vary depending on insurance coverage, pharmacy, and dosage. Many pharmaceutical companies offer patient assistance programs to help reduce out-of-pocket expenses. Discuss pricing and financial assistance options with your doctor and insurance provider.
Fintepla is one of several treatment options for Dravet Syndrome and Lennox-Gastaut Syndrome. Other medications and therapies that may be considered include:
The choice of treatment depends on individual patient factors, seizure types, comorbidities, and response to previous therapies. Your neurologist will determine the most appropriate treatment plan.
It is important to maintain regular communication with your healthcare provider while on Fintepla. You should see a doctor immediately if you experience any of the following:
A: Yes, Fintepla is classified as a Schedule IV controlled substance due to its potential for abuse, though the risk is considered low. Your doctor will provide a prescription, and pharmacies will handle it according to controlled substance regulations.
A: The effects of Fintepla may not be immediately apparent. Because the dose is titrated slowly, it can take several weeks to reach an effective maintenance dose. Your doctor will monitor your seizure activity and side effects during this period.
A: No, Fintepla should never be stopped suddenly. Abrupt discontinuation can lead to an increase in seizure frequency or severity, including status epilepticus. If treatment needs to be stopped, your doctor will gradually reduce the dose over time.
A: The Fintepla REMS (Risk Evaluation and Mitigation Strategy) program is a specialized program designed to ensure that the benefits of the drug outweigh its serious risks, specifically valvular heart disease and pulmonary arterial hypertension. It requires prescribers, pharmacies, and patients to follow specific steps, including mandatory echocardiograms and enrollment in the program, to monitor and mitigate these risks.
A: Yes, decreased appetite and weight loss are common side effects of Fintepla. Your doctor will monitor your weight regularly during treatment.
Fintepla offers a valuable treatment option for individuals living with Dravet Syndrome and Lennox-Gastaut Syndrome, providing a pathway to better seizure control and improved quality of life. However, its effective and safe use hinges on a thorough understanding of its dosage, administration, and potential risks. Adhering strictly to your doctor's prescribed dosage, attending all scheduled monitoring appointments, and promptly reporting any concerns or side effects are paramount. By working closely with your healthcare team, you can optimize the benefits of Fintepla while minimizing potential risks, paving the way for more stable and manageable epilepsy care.
Visit Hospital
Near You
Confused about whether CBD can get you high? Understand the difference between CBD and THC, their effects on your body, and what to look for in safe, non-intoxicating CBD products.
April 1, 2026
Learn about anticoagulants and antiplatelet drugs, often called blood thinners. Understand how they prevent blood clots, when they're prescribed, their side effects, and essential safety tips for Indian readers.
April 1, 2026
Confused about Plan B and abortion pills? Understand the key differences, how they work, and their effectiveness for informed reproductive health decisions.
April 1, 2026